Episurf
Episurf Medical is a Swedish medical technology company focused on patient-specific orthopedic implants and surgical planning tools for focal cartilage damage in joints. Its core platform centers on the Episealer® implant family and the Epioscopy® image-analysis workflow, with commercial activity concentrated in Europe and selected international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCustom orthopedic implants designed for focal cartilage and bone lesions in joints.
Image analysis and workflow tools used to design and fit patient-specific implants.
Clinical evidence generation, advisory support, and implementation assistance for surgeons.
Customers
Episurf sells primarily to orthopedic surgeons, hospitals, and specialist clinics that treat cartilage damage in the knee and ankle. These buyers use the company’s patient-specific solutions to address focal lesions in patients who need joint-preserving treatment options and a faster return to activity.
Buy Episealer-based treatment solutions and planning tools to treat focal cartilage lesions.
Purchase the implants and related workflow for joint-preserving orthopedic procedures.
Adopt and evaluate the technology, helping build clinical evidence and market credibility.
Influence adoption by determining whether the treatment is reimbursed in each market.
Strategy
Episurf’s strategy is built around clinical evidence, surgeon adoption, reimbursement access, and manufacturing capability for its patient-specific implant platform. The company aims to expand its installed user base and strengthen the clinical and economic case for Episealer® in prioritized markets.
Surgeons and payers need proof of outcomes before adopting a new implant platform.
Coverage decisions determine whether the products can be used broadly in each market.
A larger user base improves credibility and supports repeat utilization.
Patient-specific implants require reliable production and delivery to support commercialization.
Geography
Episurf is headquartered in Sweden and has focused commercialization in Europe, including the Nordics, Germany, the UK, Switzerland, Benelux, and other EU markets. The company also has presence in the United States and selected Middle Eastern countries, but reported sales in some of these regions remain limited.
Risks
Episurf’s business depends on regulatory approvals, clinical outcomes, reimbursement decisions, and intellectual property protection, all of which can delay adoption or limit market access. As a medical device company with patient-specific manufacturing, it also faces execution risk around production, partner dependence, cybersecurity, and broader geopolitical or supply-chain disruptions.
- Regulatory approval riskImpact: HighLikelihood: Medium
The company must obtain approvals before selling in many markets, which can delay commercialization.
Exposure: New product and market launches
- Clinical evidence and adoption riskImpact: HighLikelihood: Medium
Surgeons and payers may not adopt the technology without strong outcomes data.
Exposure: Episealer® market penetration
- Reimbursement riskImpact: HighLikelihood: Medium
Coverage decisions directly affect whether hospitals and surgeons can use the products economically.
Exposure - Intellectual property riskImpact: MediumLikelihood: Medium
The business relies on proprietary image analysis and implant design technology.
Exposure: Technology platform and product differentiation
- Partner and personnel dependenceImpact: MediumLikelihood: Medium
Commercialization and development rely on specialized partners and key staff.
Exposure - Cybersecurity riskImpact: Medium
The company depends on IT systems for design, operations, and communication.
Exposure: Internal systems and data integrity
Accounting
Judgemental itemsThe company must judge when development projects meet criteria for asset recognition.
Impact: Affects intangible assets, amortization, and reported operating expenses
If product programs underperform, capitalized assets may need write-downs.
Impact: Can create non-cash charges and reduce equity
Right-of-use assets and lease liabilities are recognized for leased premises and equipment.
Impact: Affects EBITDA-like measures, depreciation, and leverage presentation
Subsidies may be recognized against personnel costs when conditions are met.
Impact: Can reduce reported operating expenses in qualifying periods
Business combinations require fair value allocation and may create goodwill.
Impact: Introduces valuation judgments and future impairment risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026